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Hypertension and its associated chronic com-plications remain considerable health issues 
in the United States. Hypertension is defined as 
systolic blood pressure (SBP) ≥140 mm Hg and 
diastolic blood pressure (DBP) ≥90 mm Hg.1 
According to this definition, approximately 50 
million adult Americans have hypertension, and 
three fourths of these individuals do not have 
controlled blood pressure (BP) (ie, <140/90 mm 
Hg).2,3 Many hypertensive Americans are elderly 
patients 65 years and older, and this specific 
population continues to grow. According to the US 
Census Bureau, there were 35 million Americans 
65 years and older in the 2000 census, which rep-
resents a 12% increase since 1990.4 Furthermore, 
data from the National Health and Nutrition 
Examination Survey (NHANES)3 indicate that 
the prevalence of hypertension increases with age 
(present in 65.4% of NHANES respondents 60 
years and older).
Although the average DBP decreases with 
advancing age, the average SBP increases, and the 
prevalence of isolated systolic hypertension, there-
fore, is increased.5,6 Burt and associates7 estimated 
that only 20% of older people with hypertension 
are controlled at target BPs (SBP ≤140 mm Hg 
and DBP ≤90 mm Hg), which is attributed to poor 
control of SBP.
As a consequence of elevated BP, elderly patients 
are at higher risk for myocardial infarction (MI) 
and stroke, among other complications. Elevated 
BP is a major risk factor that contributes to more 
than 500,000 strokes and 150,000 stroke deaths 
yearly in the United States and is also a major 
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Hypertension in elderly patients is common and is associated with unique challenges. This study 
examines the prevalence of comorbidities in elderly hypertensive patients and evaluates the asso-
ciation between comorbidities and other covariates with blood pressure goal attainment. Data 
were collected through retrospective review of medical records and included patient character-
istics, comorbidities, treatment-related variables, and blood pressure goal attainment. At least 1 
comorbidity was present in 88% of patients, and 61% had multiple comorbidities. The most com-
mon comorbidity was isolated systolic hypertension. The presence of diabetes or isolated systolic 
hypertension at initial visit and treatment with a thiazide diuretic at the final clinic visit were 
associated with significantly higher odds of patients not achieving blood pressure goal. A diag-
nosis of heart failure was associated with lower odds of not achieving blood pressure goal. These 
issues should be given special consideration during the evaluation, treatment selection, and long-
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risk factor in nearly 1 million MIs and 500,000 
MI deaths annually.8 These statistics reflect the 
magnitude of this health challenge for our elderly 
patients. Observational studies of more than 1 mil-
lion people (elderly and nonelderly) have shown 
that ischemic heart disease and stroke increase 
linearly as BP increases.9 BP and the risk of a car-
diovascular disease (CVD) event is independent of 
other risk factors. The higher the BP, the greater 
the risk of MI and stroke.1
The Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC 7)1 
guidelines emphasize several key messages. JNC 
7 guidelines contain updated approaches to the 
management of hypertension and incorporate 
findings from large-scale clinical trials published 
after the publication of the JNC VI guidelines.10–20 
For persons older than 50 years, SBP >140 mm 
Hg is a more important CVD risk factor than 
DBP.1 Furthermore, CVD risk factor doubles with 
each increment of 20/10 mm Hg over 115/75 
mm Hg. JNC 7 also reports that people who are 
normotensive at age 55 have a 90% lifetime risk 
of developing hypertension. An SBP of 120–139 
mm Hg or a DBP of 80–89 mm Hg is considered 
prehypertensive, a new classification in the JNC 
7 guidelines, and requires health-promoting life-
style modifications to prevent CVD.1
Although drug treatment with thiazide diuret-
ics, either alone or in combination with drugs from 
other antihypertensive classes, is recommended as 
initial therapy for patients with uncomplicated 
hypertension, JNC 7 states that there are high-
risk conditions for which other antihyperten-
sive agents may be needed. In addition, most 
patients will require 2 or more medications to 
achieve goal BP, based on the results from the 
Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT)10 and 
Controlled Onset Verapamil Investigation of 
Cardiovascular Endpoints (CONVINCE).11 JNC 
7 also emphasizes that if BP is >20/10 mm Hg 
over goal, then clinicians should consider initiat-
ing therapy with 2 agents (one of which should be 
a thiazide-type diuretic).1 In addition, the JNC 7 
guidelines highlight the important role clinicians 
have in empathizing, building trust, and helping 
to motivate the hypertensive patient.
JNC 7 identifies the following disease states as 
comorbidities that should prompt the selection 
of specific antihypertensive therapy: congestive 
heart failure (CHF), isolated systolic hypertension 
(ISH), MI, high coronary disease risk, diabetes 
mellitus (DM), chronic kidney disease (CKD), 
and recurrent stroke prevention or history of 
stroke.1 These guidelines are especially pertinent 
for elderly patients who are likely to have one or 
more of these conditions.
Although JNC 7 guidelines identify the elderly 
as a special population, the goal of antihyperten-
sive therapy for older persons is the same as that 
for the general younger population of hypertensive 
patients: decrease BP to <140/90 mm Hg.1 To pre-
vent unwanted symptoms, JNC 7 recognizes that 
the initial dose of antihypertensive medication(s) 
prescribed may need to be reduced compared 
with the initial dose used in a younger adult; how-
ever, standard doses and multiple antihypertensive 
medications may ultimately be needed to achieve 
goal BP.1 While BP targets remain unchanged from 
JNC VI for the general hypertensive population 
(goal BP, <140/90 mm Hg), JNC 7 BP targets 
for patients with diabetes and CKD have been set 
lower than those in JNC VI. The current goal for 
these patients is <130/80 mm Hg.1
The purpose of our study was to estimate the 
prevalence of specific comorbidities in elderly 
hypertensive patients and to evaluate their associ-
ation, along with the association of other clinically 
relevant covariates, with BP goal attainment.
METHODS
Design and Study Participants. This is a sec-
ondary analysis of a retrospective, observational 
study of hypertensive men and women cared for 
at a geriatric clinic associated with an academic 
medical center during the period January 1, 1998 
to December 31, 1998. Eligible patients were 
those who had been assigned an International 
Classification of Diseases, 9th Revision (ICD-9) diag-
nostic code for hypertension, had attended one or 
more clinic visits during a 12-month study obser-
vation period, were 60 years or older, and had 
confirmed hypertension based on medical chart 
review. For chart review, hypertension was defined 
as SBP ≥140 mm Hg, DBP ≥90 mm Hg, or current 
use of antihypertensive medication.21 For patients 
with diabetes or renal disease, hypertension was 
defined as SBP/DBP >130/85 mm Hg.21 Patients 
with hypertensive emergency or urgency as well 
as those with pheochromocytoma were excluded 
from the study. The comorbidities examined in 
this study were chosen to closely reflect the com-
pelling indications identified in the complete JNC 
7 report.22 The health system’s Institutional Review 
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Board for Human Subject Research approved the 
study protocol.
Data Collection and Measurements. Data were 
collected by review and extraction of information 
from medical charts at the clinic and recorded on 
a standardized data collection form. This infor-
mation was transferred into an electronic format 
in preparation for further analysis. Hypertension 
control was defined as BP levels below the thresh-
olds as measured at the final clinic visit during the 
study period. Comorbidities were defined as an 
active diagnosis or a documented history of CHF, 
ISH, MI, high coronary disease risk, DM, CKD, and 
recurrent stroke prevention or history of stroke.1 
Patients were identified as having ISH if SBP was 
>140 mm Hg and DBP was <90 mm Hg.21 For the 
purpose of this analysis, high coronary disease risk 
was further defined as the presence of 2 risk factors 
in addition to hypertension including: smoking, 
DM, dyslipidemia, age (men older than 55 and 
women older than 65 years), family history of CVD 
(any CVD in a first-degree female relative at age 
65 or younger or first-degree male relative at age 
55 or younger), or any prior cardiac event. CKD 
was identified as a baseline estimated glomerular 
filtration rate (GFR) <60 mL/min per 1.73 m2 
(corresponding roughly to serum creatinine levels 
of >1.5 mg/dL in men or >1.3 mg/dL in women) 
in the absence of any acute conditions potentially 
associated with a decreased GFR or the presence of 
albuminuria (>300 mg/d or >200 mg albumin per 
gram of creatinine).
Statistical Analyses. To measure the prevalence 
of comorbidities within a margin of error of 
5%, a sample size of 384 patients was required. 
Descriptive and inferential statistics were pre-
pared using standard spreadsheet (Microsoft Excel 
2000; Microsoft Corporation, Redmond, WA) and 
statistical (SAS 9.1., SAS Institute Inc, Cary, NC) 
software. Chi-square analysis and 2-sample t test-
ing were used for bivariate analysis of categoric 
and continuous data, respectively. Binary logistic 
regression was used to report the adjusted odds 
ratio [OR] of not achieving BP goal for variables 
of interest. The following 12 covariates were mod-
eled: age; sex; number of clinic visits during the 
study period; use of thiazide diuretic at final visit; 
combination antihypertensive therapy at final 
visit; and presence of CHF, ISH, MI, high coro-
nary disease risk, DM, CKD, and recurrent stroke 
prevention or history of stroke. Covariates were 
chosen based on our desire to control for potential 
confounding (eg, age, sex, and intensity of care 
provided), model the effect of relevant comorbid 
conditions, and evaluate associations between BP 
goal attainment and medication use. 
With respect to medication use, thiazide diuret-
ics and combination therapy were specifically 
chosen for inclusion in the modeling process to 
further explore the findings of a recent landmark 
clinical trial.10 Backward stepwise logistic regres-
sion was used initially to identify variables signifi-
cantly associated with failure to achieve BP goal. A 
final regression analysis was then performed that 
included any significant variables identified from 
the backward stepwise analysis plus covariates that 
were deemed clinically relevant. Assessment and 
selection of the final model was based on standard 
model fit statistics (percent concordance/discor-
dance, C statistic, Hosmer-Lemeshow goodness-
of-fit test, and likelihood ratio test). The ORs of 
not achieving BP goal along with 95% confidence 
intervals (CIs) were calculated for each parameter 
in the final model.
RESULTS
The study population consisted of 388 patients, 
of whom 282 (73%) patients were not at BP goal 
at the final clinic visit. The mean age of the study 
participants was 77.9±7.5 years, and 73% of the 
subjects were women (Table I). The majority of 
patients (88.1%) had at least 1 comorbid condi-
tion present, and multiple comorbidities were 
present in 235 (60.6%) patients. ISH was associ-
ated with the highest prevalence (67%), followed 







No. 388 106 (27) 282 (73) –
Sex
Men 106 (27) 32 (30) 74 (26)
.43
Women 282 (73) 74 (70) 208 (74)

















*For categoric data, values in parentheses are per-
centages. Between-group comparisons performed 
by chi-square analysis. Continuous data are pre-
sented as mean ± SD (range). Between-group com-
parisons performed by 2-sample t test. BP indicates 
blood pressure.
The American Journal of Geriatric Cardiology (ISSN 1076-7460) is published bimonthly (Jan., March, May, July, Sept., Nov.) by Le Jacq, Three Parklands Drive, Darien, CT 06820-3652. Copyright ©2006 by Le Jacq.  
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, 
without permission in writing from the publishers. The opinions and ideas expressed in this publication are those of the authors and do not necessarily reflect those of the Editors or Publisher. For copies in excess of 25 
or for commercial purposes, please contact Sarah Howell at showell@lejacq.com or 203.656.1711 x106.
®
INFLUENCE OF COMORBIDITIES ON BP GOAL 27THE AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY 2007  VOL. 16  NO. 1
by high CAD risk (64.18%), DM (21.39%), stroke 
(14.69%), CHF (13.14%), MI (9.79%), and CKD 
(2.32%) (Table II). The most prevalent multiple 
comorbidity scenario was ISH and DM (15% of 
patients). Other common profiles were ISH and 
stroke (10%), ISH and CHF (8%), and ISH and 
MI (6%). A majority of patients (63%) were receiv-
ing combination therapy at their final visit during 
the study observation period. BP goal attainment 
was not significantly different in patients who were 
(25%) and were not (30%) receiving combina-
tion antihypertensive therapy from unadjusted, 
bivariate analysis (P=.13). A thiazide diuretic was 
utilized in 38% of patients and, of these, it was 
part of a combination regimen in 91% of cases. 
Among patients receiving combination therapy, 
BP goal attainment occurred in 19% and 32% of 
cases when thiazide diuretics were and were not 
included, respectively (P=.01).
Binary logistic regression analysis of all modeled 
covariates (full model) demonstrated that the pres-
ence of ISH at initial visit (OR, 1.64; 95% CI, 1.01–
2.68) and DM (OR, 4.08; 95% CI, 1.87–8.89) were 
significantly associated with patients not achieving 
goal BP. In contrast, the presence of CHF was asso-
ciated with lower odds of not achieving BP goals 
(OR, 0.36; 95% CI, 0.17–0.76). Statistically signifi-
cant associations were not found for the following 
variables: age, sex, high CAD risk, MI, CKD, and 
patients with a history of stroke  (Table III).
Backward stepwise logistic regression identified 
3 covariates that were associated with higher odds 
(DM, ISH at initial visit, and thiazide use at final 
visit) and 1 covariate associated with lower odds 
of not achieving BP goal (CHF) at final clinic visit 
during the study. To adjust for combination anti-
hypertensive therapy at final visit and intensity of 
follow-up (as measured by number of clinic visits 
during the study), these variables were added back 
into the final logistic regression analysis (Table 
IV). The addition of age and sex did not result 
in a significant improvement in the final regres-
sion model (nonsignificant likelihood ratio test; 
P=.202) and were not included. Therefore, in our 
final model, the adjusted odds of not achieving 
BP goal were higher for patients with DM (OR, 
3.33; 95% CI, 1.63–6.81), ISH (OR, 1.67; 95% CI, 
1.03–2.69), and who were using a thiazide diuretic 
at final visit (OR, 1.82; 95% CI, 1.02–3.25). The 
adjusted odds of patients not achieving BP goals 
were lower in patients with CHF (OR, 0.37; 
95% CI, 0.19–0.74). Regression adequacy statistics 
suggest a favorable model fit.








No. 388 106 282 –
Congestive 
heart failure





260 (67) 60 (23) 200 (77) .008
Myocardial 
infarction
38 (10) 15 (39) 23 (61) .08
High coronary 
disease risk
249 (64) 72 (29) 177 (71) .34
Diabetes 
mellitus
83 (21) 12 (14) 71 (86) .003
Chronic kid-
ney disease






57 (15) 16 (28) 41 (72) .89
*Values in parentheses are percentages. Between-
group comparisons performed by chi-square analysis 
unless otherwise indicated. †Fisher exact test. BP 
indicates blood pressure.
Table III. Full Logistic Regression Model: Odds 









Age 1.03 1.00 1.07
Sex 0.96 0.56 1.62
High coronary artery 
disease risk
0.70 0.40 1.23
Diabetes mellitus 4.08 1.87 8.89
Congestive heart failure 0.36 0.17 0.76
Myocardial infarction 0.67 0.31 1.44
Chronic kidney disease 1.07 0.18 6.31
History of stroke 0.86 0.44 1.71
ISH (at initial visit) 1.64 1.01 2.68
No. of clinic visits 1.03 0.92 1.16
Thiazide (at final visit) 1.66 0.91 3.01
Combination hyperten-
sion therapy  
(at final visit)
1.13 0.63 2.02
*Model fit statistics: percent concordant, 70.0; percent 
discordant, 29.5; C statistic, 0.70; Hosmer-Lemeshow 
chi-square, 8.00; P=.43. CI indicates confidence inter-
val; ISH, isolated systolic hypertension.
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DISCUSSION
Our findings demonstrate that comorbidities are 
present in the majority of geriatric hypertensive 
patients and that approximately two thirds of 
these patients have multiple comorbidities. As 
expected, ISH was quite common, present in two 
thirds of these patients, and 1 in 5 had diabetes. 
Further, ISH occurs regularly in patients with DM 
(15% of cases). Other combinations of comorbidi-
ties were also present. An important challenge for 
health care providers while managing patients 
with hypertension is selecting the appropriate 
antihypertensive agent or combination of agents 
to optimize the use of evidence-based therapies 
across multiple chronic disease states.
Of highest clinical relevance is the fact that 
patients with either ISH or DM had increased 
adjusted odds of not reaching their BP goals. With 
respect to ISH, this may reflect a general under-
appreciation for the associated cardiovascular 
risk and the importance of optimal control. The 
presence of CHF was associated with a greater 
likelihood of a patient being at or below their BP 
goal during the final clinic visit during our study 
period. These statistical findings correlate well 
with the known hemodynamic consequences of 
heart failure.
As confirmed by multiple clinical trials, thiazide 
diuretics remain an important initial treatment 
option for patients with hypertension;1 however, 
our findings suggest that the use of these agents 
was associated with a higher chance of patients 
not achieving their BP goal as defined by JNC 7 
even when they are used as part of a combination 
regimen. Our study design does not allow us to 
make conclusions regarding causes for this rela-
tionship. Previous work suggests that adherence or 
persistence with diuretics is often lower than with 
other classes of antihypertensive agents. This may 
provide a partial explanation for our findings.23,24 
When ISH is a primary concern, previous treat-
ment guidelines (JNC VI)21 and controlled trial 
evidence (Systolic Hypertension in Europe [Syst-
EUR] study)25 suggest that a long-acting dihydro-
pyridine calcium channel blocker (eg, amlodip-
ine or felodipine) is an appropriate option for 
geriatric patients. In patients with multiple risk 
factors or those with diabetes or renal insufficien-
cy, angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers are good, evidence-
based options.1
An important point to consider with respect to 
our study methods is that creatinine alone does 
not reflect true GFR in the same way that JNC 7 
defines renal insufficiency (GFR <60 mL/min). 
Therefore, it is possible that even more people 
in our study have renal insufficiency than we 
estimate. If this is the case, more patients in our 
cohort would require even more aggressive BP 
treatment, likely with careful inhibition of the 
renin–angiotensin system with close attention to 
serum potassium and GFR.
Treatment of geriatric patients, especially those 
who have multiple comorbidities, should be guided 
by current evidence-based recommendations (eg, 
JNC 7). These findings identify specific patient 
variables that are most likely to influence BP goal 
attainment in the geriatric population. Importantly, 
this population has a high short-term risk for CVD 
and relatively low rates of strict BP control.26 
Additional work is needed to assist clinicians in 
selecting the best strategies to overcome these 
comorbidity- and medication-related challenges.
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